DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 196 filers reported holding DENALI THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.71 and the average weighting 0.3%.
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 6,110,732 | $180,327,701 | 18.83% |
| ARCH Venture Management, LLC | 693,749 | $20,472,533 | 12.64% |
| Flagship Pioneering Inc. | 2,619,968 | $77,315,256 | 3.45% |
| Casdin Capital, LLC | 1,300,000 | $38,363,000 | 3.35% |
| Yiheng Capital Management, L.P. | 1,150,684 | $33,956,685 | 1.84% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 188,000 | $5,538,480 | 1.69% |
| SECTORAL ASSET MANAGEMENT INC | 245,291 | $7,238,537 | 1.21% |
| Temasek Holdings (Private) Ltd | 6,895,992 | $203,500,724 | 1.18% |
| Clarius Group, LLC | 378,267 | $11,162,659 | 0.86% |
| Artal Group S.A. | 802,899 | $23,694 | 0.73% |